Management of venous thromboembolism in patients with cancer: role of dalteparin

References

• Alhenc-GelasMJestin-Le GuernicCVitouxJFFragmin-Study GroupAdjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosisThromb Haemost1994716987027974334
   PubMed Web of Science ®Google Scholar
• AnonymousFragmin (dalteparin sodium) Product Monograph2006
   Google Scholar
• AujeskyDSmithKJCornuzJCost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolismThromb Haemost2005935929915735815
   PubMed Web of Science ®Google Scholar
• BergqvistDRisk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxisJ Surg Oncol2007951677417262765
   PubMed Web of Science ®Google Scholar
• BergqvistDAgnelliGCohenATDuration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancerN Engl J Med20023469758011919306
   PubMed Web of Science ®Google Scholar
• BlomJWDoggenCJOsantoSMalignancies, prothrombotic mutations, and the risk of venous thrombosisJAMA20052937152215701913
   PubMed Web of Science ®Google Scholar
• BlomJWVanderschootJPOostindierMJIncidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage studyJ Thromb Haemost200645293516460435
   PubMed Web of Science ®Google Scholar
• BoneuBde MoerloosePHow and when to monitor a patient treated with low molecular weight heparinSemin Thromb Hemost2001275192211668422
   PubMed Web of Science ®Google Scholar
• BrattGTornebohmEWidlundLLow molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteersThromb Res198642613203715820
   PubMed Web of Science ®Google Scholar
• BrombergMEKonigsbergWHMadisonJFTissue factor promotes melanoma metastasis by a pathway independent of blood coagulationProc Natl AcadSci USA19959282059
   PubMed Web of Science ®Google Scholar
• BullerHRAgnelliGHullRDAntithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyChest2004126401S28S15383479
   PubMed Web of Science ®Google Scholar
• BullerHRvan DoormaalFFvan SluisGLCancer and thrombosis: from molecular mechanisms to clinical presentationsJ Thromb Haemost20075Suppl 12465417635733
   PubMedGoogle Scholar
• ChewHKWunTHarveyDIncidence of venous thromboembolism and its effect on survival among patients with common cancersArch Intern Med20061664586416505267
   PubMed Web of Science ®Google Scholar
• CollignonFFrydmanACaplainHComparison of the pharmacokinetic profiles of three low molecular mass heparins – dalteparin, enoxaparin and nadroparin – administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)Thromb Haemost199573630407495071
   PubMed Web of Science ®Google Scholar
• CoubanSGoodyearMBurnellMRandomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancerJ Clin Oncol2005234063915767639
   PubMed Web of Science ®Google Scholar
• CroninCGLohanDGKeaneMPrevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CTAJR Am J Roentgenol20071891627017579167
   PubMed Web of Science ®Google Scholar
• DeitcherSRGomesMPThe risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic reviewCancer20041014394915274057
   PubMed Web of Science ®Google Scholar
• DeitcherSRKesslerCMMerliGSecondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day periodClin Appl Thromb Hemost2006123899617000884
   PubMed Web of Science ®Google Scholar
• DranitsarisGVincentMCrowtherMDalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysisPharmacoeconomics20062459360716761906
   PubMed Web of Science ®Google Scholar
• DunnCJJarvisBDalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseaseDrugs2000602033710929935
   PubMed Web of Science ®Google Scholar
• El AccaouiRNShamseddeenWATaherATThalidomide and thrombosis. A meta-analysisThromb Haemost2007971031617549307
   PubMed Web of Science ®Google Scholar
• ENOXACAN Study GroupEfficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study GroupBr J Surg19978410991039278651
   PubMed Web of Science ®Google Scholar
• FareedJLeongWLHoppensteadtDAGeneric low-molecular-weight heparins: some practical considerationsSemin Thromb Hemost2004307031315630677
   PubMed Web of Science ®Google Scholar
• FiessingerJNLopez-FernandezMGattererEOnce-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosisThromb Haemost19967619598865530
   PubMed Web of Science ®Google Scholar
• FrickerJPVergnesYSchachRLow dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgeryEur J Clin Invest19881856172852111
   PubMed Web of Science ®Google Scholar
• GaleAJGordonSGUpdate on tumor cell procoagulant factorsActa Haematol2001106253211549774
   PubMed Web of Science ®Google Scholar
• GeertsWHPineoGFHeitJAPrevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyChest2004126338S400S15383478
   PubMed Web of Science ®Google Scholar
• GouldMKDembitzerADDoyleRLLow-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trialsAnn Intern Med1999130800910366369
   PubMed Web of Science ®Google Scholar
• GrignaniGMaioloACytokines and hemostasisHaematologica20008596797210980636
   PubMed Web of Science ®Google Scholar
• HaddadTCGreenoEWChemotherapy-induced thrombosisThromb Res20061185556816388837
   PubMed Web of Science ®Google Scholar
• HandelandGFAbildgaardUHolmHADose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparinEur J Clin Pharmacol199039107122174783
   PubMed Web of Science ®Google Scholar
• HarenbergJHuckKBratschHTherapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosisHaemostasis199020Suppl 1205191964663
   PubMedGoogle Scholar
• HeitJAMohrDNSilversteinMDPredictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort studyArch Intern Med2000a160761810737275
   PubMed Web of Science ®Google Scholar
• HeitJASilversteinMDMohrDNRisk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control studyArch Intern Med2000b1608091510737280
   PubMed Web of Science ®Google Scholar
• HerbstRSSandlerABNon-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?Oncologist20049Suppl 1192615178812
   PubMedGoogle Scholar
• HirshJRisk of thrombosis with lenalidomide and its prevention with aspirinChest2007131275717218586
   PubMed Web of Science ®Google Scholar
• HirshJRaschkeRHeparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyChest2004126188S203S15383472
   PubMed Web of Science ®Google Scholar
• HolmHALyBHandelandGFSubcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparinHaemostasis198616Suppl 23073527886
   PubMedGoogle Scholar
• HullJHHullPJDalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancerN Engl J Med20033491385714526768
   PubMedGoogle Scholar
• HullRDPineoGFBrantRFLong-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancerAm J Med200611910627217145251
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med200435023354215175435
   PubMed Web of Science ®Google Scholar
• HuttenBAPrinsMHGentMIncidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysisJ Clin Oncol20001830788310963635
   PubMed Web of Science ®Google Scholar
• KabbinavarFHurwitzHIFehrenbacherLPhase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerJ Clin Oncol20032160512506171
   PubMed Web of Science ®Google Scholar
• KakkarAKHaasSWolfHEvaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudyThromb Haemost2005948677116270644
   PubMed Web of Science ®Google Scholar
• KarthausMKretzschmarAKroningHDalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trialAnn Oncol2006172899616317012
   PubMed Web of Science ®Google Scholar
• KearonCGinsbergJSJulianJAComparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolismJAMA20062969354216926353
   PubMed Web of Science ®Google Scholar
• KovacsMJLevineMNKeeneyMAnti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patientsThromb Haemost20059311858815968406
   PubMed Web of Science ®Google Scholar
• LaupacisAFeenyDDetskyASHow attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluationsCMAJ1992146473811306034
   PubMed Web of Science ®Google Scholar
• LeeAYLevineMNVenous thromboembolism and cancer: risks and outcomesCirculation2003107I17I2112814981
   PubMed Web of Science ®Google Scholar
• LeeAYLevineMNBakerRILow-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancerN Engl J Med20033491465312853587
   PubMed Web of Science ®Google Scholar
• LeeAYLevineMNButlerGIncidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancerJ Clin Oncol2006241404816549834
   PubMed Web of Science ®Google Scholar
• LeizoroviczASimonneauGDecoususHComparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysisBMJ19943092993048086867
   PubMed Web of Science ®Google Scholar
• LevineRLMcCollumDHurstingMJHow frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?Chest2006130681716963663
   PubMed Web of Science ®Google Scholar
• LindmarkerPHolmstromMGranqvistSComparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosisThromb Haemost199472186907831649
   PubMed Web of Science ®Google Scholar
• LuomanmakiKGrankvistSHallertCA multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosisJ Intern Med199624085928810934
   PubMed Web of Science ®Google Scholar
• MeyerGBrenotFPacouretGSubcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot studyThromb Haemost19957414324358772215
   PubMed Web of Science ®Google Scholar
• MeyerGMarjanovicZValckeJComparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled studyArch Intern Med200216217293512153376
   PubMed Web of Science ®Google Scholar
• MismettiPLaporteSDarmonJYMeta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgeryBr J Surg2001889133011442521
   PubMed Web of Science ®Google Scholar
• MonrealMZacharskiLJimenezJAFixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort studyJ Thromb Haemost2004213111515304036
   PubMed Web of Science ®Google Scholar
• NobleSIFinlayIGIs long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative studyPalliat Med20051919720115920933
   PubMed Web of Science ®Google Scholar
• NobleSIHoodKFinlayIGThe use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patientsPalliat Med200721473617846086
   PubMed Web of Science ®Google Scholar
• OttenHMMathijssenJtenCHSymptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenonArch Intern Med2004164190414744843
   PubMed Web of Science ®Google Scholar
• PrandoniPFalangaAPiccioliACancer and venous thromboembolismLancet Oncol200564011015925818
   PubMed Web of Science ®Google Scholar
• PrandoniPLensingAWPiccioliARecurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood20021003484812393647
   PubMed Web of Science ®Google Scholar
• QuinlanDJMcQuillanAEikelboomJWLow-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trialsAnn Intern Med20041401758314757615
   PubMed Web of Science ®Google Scholar
• RabbatCGCookDJCrowtherMADalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiencyJ Crit Care2005203576316310608
   PubMed Web of Science ®Google Scholar
• RajkumarSVBloodELenalidomide and venous thrombosis in multiple myelomaN Engl J Med200635420798016696148
   PubMed Web of Science ®Google Scholar
• RakJYuJLLuyendykJOncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humansCancer Res20066610643617108099
   PubMed Web of Science ®Google Scholar
• RasmussenMSJorgensenLNWille-JorgensenPProlonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label studyJ Thromb Haemost2006423849016881934
   PubMed Web of Science ®Google Scholar
• RasmussenMSWillie-JorgensenPJorgensenLNExtended out-of-hospital low-molecular-weight heparin prophylaxis against venous thromboembolism in patients after cancer operations: a meta-analysisJ Thromb Haemost20053Suppl 1 Abstract P2213
   PubMedGoogle Scholar
• RicklesFRPatiernoSFernandezPMTissue factor, thrombin, and cancerChest200312458S68S12970125
   PubMed Web of Science ®Google Scholar
• RugoHSBevacizumab in the treatment of breast cancer: rationale and current dataOncologist20049Suppl 1434915178815
   PubMed Web of Science ®Google Scholar
• SallahSWanJYNguyenNPVenous thrombosis in patients with solid tumors: determination of frequency and characteristicsThromb Haemost200287575912008937
   PubMed Web of Science ®Google Scholar
• ShahMAIlsonDKelsenDPThromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapyJ ClinOncol20052325746
   PubMed Web of Science ®Google Scholar
• SimoneauGBergmannJFKherAPharmacokinetics of a low molecular weight heparin [Fragmin] in young and elderly subjectsThromb Res19926660371326135
   PubMed Web of Science ®Google Scholar
• SorensenHTMellemkjaerLOlsenJHPrognosis of cancers associated with venous thromboembolismN Engl J Med200034318465011117976
   PubMed Web of Science ®Google Scholar
• TagalakisVLeviDAgulnikJSHigh risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patientsJ Thorac Oncol200727293417762339
   PubMed Web of Science ®Google Scholar
• VersoMAgnelliGBertoglioSEnoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patientsJ Clin Oncol20052340576215767643
   PubMed Web of Science ®Google Scholar
• von TempelhoffGFDietrichMHommelGBlood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancerJ Clin Oncol199614256088823336
   PubMed Web of Science ®Google Scholar
• von TempelhoffGFNiemannFSchneiderDMBlood rheology during chemotherapy in patients with ovarian cancerThromb Res19989073829684760
   PubMed Web of Science ®Google Scholar
• WellsPSAndersonDRRodgerMAA randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolismArch Intern Med2005165733815824291
   PubMed Web of Science ®Google Scholar
• ZonderJABarlogieBDurieBGThrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxisBlood2006108403416790586
   PubMed Web of Science ®Google Scholar